Table 1.
Interpretation of the results of MIC for antifungal drugs against vaginal yeasts of C. albicans (n = 58) and non-C. albicans (n = 31).
| Candida albicans | Non-Candida albicans | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antifungals | Sa | DDSb | Rc | S | DDS | R | ||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| FLU | 55 | 94.8 | 3 | 5.2 | — | — | 26 | 83.9 | 5 | 16.1 | — | — |
| ITRA | 48 | 82.8 | 4 | 6.9 | 6 | 10.3 | 18 | 58.1 | 4 | 12.9 | 9 | 29.0 |
| KETO | 20 | 34.5 | 23 | 9.7 | 15 | 25.8 | 9 | 29.0 | 7 | 22.6 | 15 | 48.4 |
| MICO | 42 | 72.4 | 14 | 24.1 | 2 | 3.5 | 6 | 19.4 | 20 | 64.5 | 5 | 16.1 |
| VORI | 57 | 98.3 | 1 | 1.7 | — | — | 30 | 96.8 | 1 | 3.2 | — | — |
| AMB | 57 | 98.3 | — | — | 1 | 1.7 | 31 | 100.0 | — | — | — | — |
DDS, dose-dependent susceptibility; R, resistant.
aS: Isolates with MIC ≤ 8 μg mL–1 for FLU, ≤0.125 μg mL-1 for ITRA, KETO, and MICO, and ≤1 μg mL–1 for AMB and VORI, bDDS: Endpoints for antifungal agents: isolates with MIC between 16 and 32 μg mL–1 for FLU, 0.25–0.5 μg mL–1 for ITRA, KETO, and MICO, and 2 μg mL–1 for VORI, cR: Isolates with MIC ≥ 64 μg mL–1 for FLU, ≥1 μg mL–1 for ITRA, KETO, and MICO, ≥ 4 μg mL–1 for VORI and ≥2 μg mL–1 for AMB.